Accéder au contenu
MilliporeSigma
Toutes les photos(1)

Documents

F0250000

Fluorouracil

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

5-Fluorouracil, 2,4-Dihydroxy-5-fluoropyrimidine, 5-FU, 5-Fluoro-2,4(1H,3H)-pyrimidinedione

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C4H3FN2O2
Numéro CAS:
51-21-8
Poids moléculaire :
130.08
Numéro Beilstein :
127172
Numéro MDL:
MFCD00006018
Code UNSPSC :
41116107
ID de substance PubChem :
329799645
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

fluorouracil

Fabricant/nom de marque

EDQM

Pf

282-286 °C (dec.) (lit.)

Application(s)

pharmaceutical (small molecule)

Format

neat

Température de stockage

2-8°C

Chaîne SMILES 

FC1=CNC(=O)NC1=O

InChI

1S/C4H3FN2O2/c5-2-1-6-4(9)7-3(2)8/h1H,(H2,6,7,8,9)

Clé InChI

GHASVSINZRGABV-UHFFFAOYSA-N

Informations sur le gène

human ... TYMS(7298)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Catégories apparentées

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Fluorouracil EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

Y0000762

Fluorouracil impurity A, European Pharmacopoeia (EP) Reference Standard

Y0000763

Fluorouracil impurity B, European Pharmacopoeia (EP) Reference Standard

Y0000791

Fluorouracil impurity mixture, European Pharmacopoeia (EP) Reference Standard

Y0000765

Fluorouracil impurity F, European Pharmacopoeia (EP) Reference Standard

Y0000764

Uracile, European Pharmacopoeia (EP) Reference Standard

1279000

Fluorouracil, United States Pharmacopeia (USP) Reference Standard

1279054

Fluorouracil Related Compound E, United States Pharmacopeia (USP) Reference Standard

1279065

Fluorouracil Related Compound F, United States Pharmacopeia (USP) Reference Standard

1279019

Fluorouracil Related Compound A, United States Pharmacopeia (USP) Reference Standard

1279021

Fluorouracil Related Compound B, United States Pharmacopeia (USP) Reference Standard

BP995

Fluorouracil, British Pharmacopoeia (BP) Reference Standard

PHR2584

5,6-Diamino-1,3-dimethyluracil, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2865

Fluorouracil Related Compound A, certified reference material, pharmaceutical secondary standard

PHR2866

Fluorouracil Related Compound B, pharmaceutical secondary standard, certified reference material

PHR2867

Fluorouracil Related Compound E, certified reference material, pharmaceutical secondary standard

PHR2868

Fluorouracil Related Compound F, certified reference material, pharmaceutical secondary standard

Pictogrammes

Skull and crossbonesHealth hazard
GHS06,GHS08

Mention d'avertissement

Danger

Mentions de danger

H301,H351

Classification des risques

Acute Tox. 3 Oral - Carc. 2

Code de la classe de stockage

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe de danger pour l'eau (WGK)

WGK 3

Choose from one of the most recent versions:

Certificats d'analyse (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Slide 1 of 6

1 of 6

Gemcitabine hydrochloride European Pharmacopoeia (EP) Reference Standard

Y0000675

Gemcitabine hydrochloride

5-Fluorouracil ≥99% (HPLC), powder

Sigma-Aldrich

F6627

5-Fluorouracil

5-Fluorouracil for synthesis

Sigma-Aldrich

8.18505

5-Fluorouracil

5-Fluorouracil Potent antitumor agent.

Sigma-Aldrich

343922

5-Fluorouracil

Oxaliplatine Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1528

Oxaliplatine

7-Ethyl-10-hydroxycamptothecin ≥98% (HPLC), powder

Sigma-Aldrich

H0165

7-Ethyl-10-hydroxycamptothecin

Tania Diaz et al.
Journal of surgical oncology, 109(7), 676-683 (2014-02-11)
Surgery is the standard treatment for colorectal cancer (CRC), and adjuvant chemotherapy has been shown to be effective in stage III but less so in stage II. We have analyzed the expression of the miR-200 family in tissue samples from
André Bp van Kuilenburg et al.
Pharmacogenomics, 14(7), 799-811 (2013-05-09)
5-fluorouracil (5-FU) remains the cornerstone of all currently applied regimens for the treatment of patients with cancers of the gastrointestinal tract, breast, and head and neck. Unfortunately, a large variation in the clearance of 5-FU has been observed between patients
Guido Deboever et al.
Clinical colorectal cancer, 12(1), 8-14 (2012-10-30)
Most chemotherapy regimens in colorectal cancer treatment are 5-fluorouracil (5-FU)/leucovorin or capecitabine-based. Cardiotoxicity is a less common but potentially lethal complication of 5-FU or capecitabine treatment, and some physicians might be unfamiliar with treatment alternatives. Rechallenging should be avoided because
Anne Polk et al.
Cancer treatment reviews, 39(8), 974-984 (2013-04-16)
To systematically review the incidence, manifestations and predisposing factors for cardiovascular toxicity in cancer patients treated with systemic 5-fluorouracil or capecitabine. We searched PubMed, EMBASE and Web of science for studies with ≥ 20 cancer patients evaluating cardiovascular toxicity of
John M L Ebos et al.
EMBO molecular medicine, 6(12), 1561-1576 (2014-11-02)
Thousands of cancer patients are currently in clinical trials evaluating antiangiogenic therapy in the neoadjuvant setting, which is the treatment of localized primary tumors prior to surgical intervention. The rationale is that shrinking a tumor will improve surgical outcomes and
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique